Home
/
HALOZYME THERAPEUTICS, INC.
/
Financials
/
Quarterly
HALOZYME THERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that HALOZYME THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$25.56M
Nov 6, 2018
Q2
2018
Jun 30, 2018
$35.20M
Aug 7, 2018
Q1
2018
Mar 31, 2018
$30.87M
May 10, 2018
Q3
2018
Sep 30, 2017
$63.73M
Nov 6, 2018
Q2
2018
Jun 30, 2017
$33.75M
Aug 7, 2018
Q1
2018
Mar 31, 2017
$29.57M
May 10, 2018
Q3
2017
Sep 30, 2016
$31.85M
Nov 7, 2017
Q2
2017
Jun 30, 2016
$33.34M
Aug 8, 2017
Q1
2017
Mar 31, 2016
$42.50M
May 9, 2017
Q3
2016
Sep 30, 2015
$20.78M
Nov 7, 2016
Q2
2016
Jun 30, 2015
$43.38M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$18.67M
May 9, 2016
Q3
2015
Sep 30, 2014
$14.61M
Nov 9, 2015
Q2
2015
Jun 30, 2014
$18.39M
Aug 10, 2015
Q1
2015
Mar 31, 2014
$11.97M
May 11, 2015
Q3
2014
Sep 30, 2013
$16.01M
Nov 10, 2014
Q2
2014
Jun 30, 2013
$14.45M
Aug 11, 2014
Q1
2014
Mar 31, 2013
$11.83M
May 12, 2014
Q3
2013
Sep 30, 2012
$5.33M
Nov 8, 2013
Q2
2013
Jun 30, 2012
$7.76M
Aug 7, 2013
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$354.26M
Nov 3, 2025
Q2
2025
Jun 30, 2025
$325.72M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$264.86M
May 6, 2025
Q3
2025
Sep 30, 2024
$290.08M
Nov 3, 2025
Q2
2025
Jun 30, 2024
$231.35M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$195.88M
May 6, 2025
Q3
2024
Sep 30, 2023
$216.03M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$221.04M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$162.14M
May 7, 2024
Q3
2023
Sep 30, 2022
$208.98M
Nov 6, 2023
Q2
2023
Jun 30, 2022
$152.37M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$117.28M
May 9, 2023
Q3
2022
Sep 30, 2021
$115.83M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$136.46M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$89.02M
May 10, 2022
Q3
2021
Sep 30, 2020
$65.32M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$55.22M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$25.35M
May 10, 2021
Q3
2020
Sep 30, 2019
$46.23M
Nov 2, 2020
Q2
2020
Jun 30, 2019
$39.15M
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$175.23M
Nov 3, 2025
Q2
2025
Jun 30, 2025
$165.16M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$118.10M
May 6, 2025
Q3
2025
Sep 30, 2024
$137.01M
Nov 3, 2025
Q2
2025
Jun 30, 2024
$93.25M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$76.82M
May 6, 2025
Q3
2024
Sep 30, 2023
$81.84M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$74.75M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$39.62M
May 7, 2024
Q3
2023
Sep 30, 2022
$61.63M
Nov 6, 2023
Q2
2023
Jun 30, 2022
$22.69M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$60.11M
May 9, 2023
Q3
2022
Sep 30, 2021
$216.59M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$91.46M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$27.90M
May 10, 2022
Q3
2021
Sep 30, 2020
$36.21M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$25.82M
Aug 9, 2021
Q1
2021
Mar 31, 2020
($6.10M)
May 10, 2021
Q3
2020
Sep 30, 2019
($25.02M)
Nov 2, 2020
Q2
2020
Jun 30, 2019
($14.62M)
Aug 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$217.92M
Nov 3, 2025
Q2
2025
Jun 30, 2025
$202.44M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$141.54M
May 6, 2025
Q3
2025
Sep 30, 2024
$163.20M
Nov 3, 2025
Q2
2025
Jun 30, 2024
$117.24M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$95.54M
May 6, 2025
Q3
2024
Sep 30, 2023
$88.28M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$94.46M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$53.80M
May 7, 2024
Q3
2023
Sep 30, 2022
$83.29M
Nov 6, 2023
Q2
2023
Jun 30, 2022
$34.06M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$75.67M
May 9, 2023
Q3
2022
Sep 30, 2021
$75.59M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$93.05M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$50.74M
May 10, 2022
Q3
2021
Sep 30, 2020
$40.30M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$29.56M
Aug 9, 2021
Q1
2021
Mar 31, 2020
($3.22M)
May 10, 2021
Q3
2020
Sep 30, 2019
($24.54M)
Nov 2, 2020
Q2
2020
Jun 30, 2019
($13.98M)
Aug 10, 2020